A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with L-Carnitine Improves Biocompatibility on Human Mesothelial Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 30

PMID 33374405

Citations 11

Authors

Francesca Piccapane

Mario Bonomini

Giuseppe Castellano

Andrea Gerbino

Monica Carmosino

Maria Svelto

Arduino Arduini

Giuseppe Procino

Affiliations

Soon will be listed here.

Abstract

The main reason why peritoneal dialysis (PD) still has limited use in the management of patients with end-stage renal disease (ESRD) lies in the fact that the currently used glucose-based PD solutions are not completely biocompatible and determine, over time, the degeneration of the peritoneal membrane (PM) and consequent loss of ultrafiltration (UF). Here we evaluated the biocompatibility of a novel formulation of dialytic solutions, in which a substantial amount of glucose is replaced by two osmometabolic agents, xylitol and l-carnitine. The effect of this novel formulation on cell viability, the integrity of the mesothelial barrier and secretion of pro-inflammatory cytokines was evaluated on human mesothelial cells grown on cell culture inserts and exposed to the PD solution only at the apical side, mimicking the condition of a PD dwell. The results were compared to those obtained after exposure to a panel of dialytic solutions commonly used in clinical practice. We report here compelling evidence that this novel formulation shows better performance in terms of higher cell viability, better preservation of the integrity of the mesothelial layer and reduced release of pro-inflammatory cytokines. This new formulation could represent a step forward towards obtaining PD solutions with high biocompatibility.

Citing Articles

Coupling Osmotic Efficacy with Biocompatibility in Peritoneal Dialysis: A Stiff Challenge.

Bonomini M, Masola V, Monaco M, Sirolli V, Di Liberato L, Prosdocimi T Int J Mol Sci. 2024; 25(6).

PMID: 38542505 PMC: 10971259. DOI: 10.3390/ijms25063532.

Human peritoneal tight junction, transporter and channel expression in health and kidney failure, and associated solute transport.

Levai E, Marinovic I, Bartosova M, Zhang C, Schaefer B, Jenei H Sci Rep. 2023; 13(1):17429.

PMID: 37833387 PMC: 10575882. DOI: 10.1038/s41598-023-44466-z.

Steviol glycosides as an alternative osmotic agent for peritoneal dialysis fluid.

Kopytina V, Pascual-Anton L, Toggweiler N, Arriero-Pais E, Strahl L, Albar-Vizcaino P Front Pharmacol. 2022; 13:868374.

PMID: 36052133 PMC: 9424724. DOI: 10.3389/fphar.2022.868374.

Proteomics and Extracellular Vesicles as Novel Biomarker Sources in Peritoneal Dialysis in Children.

Trincianti C, Meleca V, La Porta E, Bruschi M, Candiano G, Garbarino A Int J Mol Sci. 2022; 23(10).

PMID: 35628461 PMC: 9144397. DOI: 10.3390/ijms23105655.

Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.

Masola V, Bonomini M, Borrelli S, Di Liberato L, Vecchi L, Onisto M Int J Mol Sci. 2022; 23(9).

PMID: 35563220 PMC: 9102299. DOI: 10.3390/ijms23094831.

References

Bajo M, Peso G, Teitelbaum I . Peritoneal Membrane Preservation. Semin Nephrol. 2017; 37(1):77-92. DOI: 10.1016/j.semnephrol.2016.10.009. View

Bartosova M, Peter Schmitt C . Biocompatible Peritoneal Dialysis: The Target Is Still Way Off. Front Physiol. 2019; 9:1853. PMC: 6343681. DOI: 10.3389/fphys.2018.01853. View

Ito T, Yorioka N . Peritoneal damage by peritoneal dialysis solutions. Clin Exp Nephrol. 2008; 12(4):243-249. DOI: 10.1007/s10157-008-0032-y. View

Davies S, Phillips L, Griffiths A, Russell L, Naish P, Russell G . What really happens to people on long-term peritoneal dialysis?. Kidney Int. 1998; 54(6):2207-17. DOI: 10.1046/j.1523-1755.1998.00180.x. View

Bonomini M, Pandolfi A, Di Liberato L, Di Silvestre S, Cnops Y, Di Tomo P . L-carnitine is an osmotic agent suitable for peritoneal dialysis. Kidney Int. 2011; 80(6):645-54. DOI: 10.1038/ki.2011.117. View

Pochini L, Scalise M, Di Silvestre S, Belviso S, Pandolfi A, Arduini A . Acetylcholine and acetylcarnitine transport in peritoneum: Role of the SLC22A4 (OCTN1) transporter. Biochim Biophys Acta. 2016; 1858(4):653-60. DOI: 10.1016/j.bbamem.2015.12.026. View

Lambie M, Chess J, Donovan K, Kim Y, Do J, Lee H . Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol. 2013; 24(12):2071-80. PMC: 3839554. DOI: 10.1681/ASN.2013030314. View

Velloso M, Otoni A, Sabino A, de Castro W, Pinto S, Marinho M . Peritoneal dialysis and inflammation. Clin Chim Acta. 2013; 430:109-14. DOI: 10.1016/j.cca.2013.12.003. View

Arfeen S, Goodship T, Kirkwood A, Ward M . The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution. Clin Nephrol. 1990; 33(4):192-99. View

10.

Lee H, Yu M, Song J, Ha H . Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int. 2004; 65(4):1170-9. DOI: 10.1111/j.1523-1755.2004.00491.x. View

11.

Cendoroglo M, Sundaram S, Jaber B, Pereira B . Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. Am J Kidney Dis. 1998; 31(2):273-82. DOI: 10.1053/ajkd.1998.v31.pm9469498. View

12.

Cheng S, Lu Y, Li Y, Gao L, Shen H, Song K . Hydrogen sulfide inhibits epithelial-mesenchymal transition in peritoneal mesothelial cells. Sci Rep. 2018; 8(1):5863. PMC: 5897522. DOI: 10.1038/s41598-018-21807-x. View

13.

Vila Cuenca M, Keuning E, Talhout W, Paauw N, van Ittersum F, Ter Wee P . Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model. Int Urol Nephrol. 2018; 50(6):1151-1161. PMC: 5986835. DOI: 10.1007/s11255-018-1872-3. View

14.

Livesey G . Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. Nutr Res Rev. 2008; 16(2):163-91. DOI: 10.1079/NRR200371. View

15.

Yao V, Platell C, Hall J . Peritoneal mesothelial cells produce inflammatory related cytokines. ANZ J Surg. 2004; 74(11):997-1002. DOI: 10.1111/j.1445-1433.2004.03220.x. View

16.

Bonomini M, Di Silvestre S, Di Tomo P, Di Pietro N, Mandatori D, Di Liberato L . Effect of peritoneal dialysis fluid containing osmo-metabolic agents on human endothelial cells. Drug Des Devel Ther. 2016; 10:3925-3932. PMC: 5135076. DOI: 10.2147/DDDT.S117078. View

17.

Song P, Sekhon H, Jia Y, Keller J, Blusztajn J, Mark G . Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 2003; 63(1):214-21. View

18.

Bonomini M, Di Liberato L, Zammit V, Arduini A . Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis. Molecules. 2019; 24(19). PMC: 6803867. DOI: 10.3390/molecules24193449. View

19.

Ha H, Lee H . Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int. 2000; 20 Suppl 2:S15-8. View

20.

Wong T, Phillips A, Witowski J, Topley N . Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int. 2003; 63(4):1404-16. DOI: 10.1046/j.1523-1755.2003.00883.x. View